CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
Amantadine +1 moredrug
Likely dose
Amantadine 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02486211
NCT02486211Phase 2Completed
CompareCT.gov

Amantadine to Speed Awakening After Cardiac Arrest

Jon Rittenberger, MD·interventional·Posted Jul 1, 2015·Updated Dec 4, 2019

In Brief

A Phase 2 clinical trial evaluating Amantadine and Placebo for Coma and 2 related conditions. Completed, enrolled 14 participants across 4 sites.

Detailed Summary

This study evaluates if amantadine will increase the rate of awakening in patients resuscitated from cardiac arrest but comatose (not following commands) after their resuscitation. Half of the participants will receive amantadine and the other will receive placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsComa, Heart Arrest, Anoxia
CountriesUnited States
CollaboratorsAmerican Heart Association

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 1, 2015
Enrollment StartSep 1, 2015
Primary CompletionJun 30, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.0 years ago

Interventions

Amantadinedrug

100mg twice per day for 7 days at 0600 and 1200

Placebodrug

Placebo comparator